Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: A randomized trial

Catheterization and Cardiovascular Interventions

Volumn 67, Issue 2, 2006, Pages 288-297

  Ansel, Gary M ^a,g   Silver, Mitchell J ^a   Botti Jr , Charles F ^a   Rocha Singh, Krishna ^b   Bates, Mark C ^c   Rosenfield, Kenneth ^d   Schainfeld, Robert M ^e   Laster, Steven B ^f   Zander, Carol ^g  

^a RIVERSIDE METHODIST HOSPITAL   (United States)

^b ST JOHN'S HOSPITAL   (United States)

^c CHARLESTON AREA MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ST ELIZABETH'S MEDICAL CENTER   (United States)

^f SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^g MidWest Cardiology Research Foundation   (United States)

Author keywords

Balloon angioplasty; Duplex scan; Glycoprotein IIb IIIa; Nitinol; Randomized; Stent; Superficial femoral artery; Treadmill

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR; HEPARIN; NITINOL; PLACEBO;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTERY OCCLUSION; ARTICLE; CATHETERIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELUTING STENT; ECHOGRAPHY; FEMALE; FEMORAL ARTERY; HUMAN; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALLOYS; ANGIOGRAPHY; ANGIOPLASTY, BALLOON; ANTIBODIES, MONOCLONAL; ARTERIAL OCCLUSIVE DISEASES; CHI-SQUARE DISTRIBUTION; FEMALE; FEMORAL ARTERY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 32544454509     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20593     Document Type: Article

References (36)

1. Rutherford RB. Standards for evaluating results of interventional therapy for peripheral vascular disease. Circulation 1991;83(Suppl 2):I6-I11.
2. White GH, Liew SC, Waugh RC, Stephen MS, Harris JP, Kidd J, Sachinwalla T, Yu W, May J. Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation. J Vasc Surg 1995;21:270-279.
3. Zdanowski Z, Albrechtsson U, Lundin A, Jonung T, Ribbe E, Thome J, Norgren L. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol 1999;18:251-255.
4. Cheng SW, Ting AC, Wong J. Endovascular stenting of superficial femoral artery stenosis and occlusions: results and risk factor analysis. Cardiovasc Surg 2001;9:133-140.
5. Do dai D, Triller J, Walpoth BH, Stirnemann P, Mahler F. A comparison study of self-expandable stents vs balloon angioplasty alone in femoropopliteal artery occlusions. Cardiovasc Intervent Radiol 1992;15:306-312.
6. Gordon IL, Conroy RM, Arefi M, Tobis JM, Stemmer EA, Wilson SE. Three-year outcome of endovascular treatment of superficial femoral artery occlusion. Arch Surg 2001;136:221-228.
7. Martin EC, Katzen BT, Benenati JF, Diethrich EB, Dorros G, Graor RA, Horton KM, Iannone LA, Isner JM, Ramee SR, et al. Multicenter trial of the wallstent in the iliac and femoral arteries. J Vasc Interv Radiol 1995;6:843-849.
8. Gray BH, Sullivan TM, Childs MB, Young JR, Olin JW. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg 1997;25:74-83.
9. Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K, Lammer J. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 2001;12:23-31.
10. The Epilog Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
11. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
12. Legemate DA, Teeuwen C, Hoeneveld, Ackerstaff RGA, Eikelbloom BC. Spectral analysis criteria in duplex scanning or aortoiliac and femoropopliteal arterial disease. Ultrasound Med Biol 1991;17:769-776.
13. Koelemay MJ, Legemate DA, De Vos H, van Gurp A, Balm R, Reekers JA, Jacobs MJ. Duplex scanning allows selective use of arteriography in the management of patients with severe lower leg arterial disease. J Vasc Surg 2001;34:661-667.
14. Collett D. Modeling Binary Data. London: Chapman & Hall 2003.
15. Ndrepepa G, Kastrati A, Neumann FJ, Schmitt C, Mehilli J, Schomig A. Five-year outcome of patients with acute myocardial infarction enrolled in a randomized trial assessing the value of abciximab during coronary artery stenting. Eur Heart J 2004;25:1635-1640.
16. Bhatt DL, Marso SP, Lincoff AM, Welski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-928.
17. Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleimen NS, Hammond T, Booth JE, Sapp SK, Topol EJ. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet 2b/3a inhibitor for stenting trial) diabetic substudy. Circulation 1999;100:2477-2484.
18. Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-st segment elevation acute coronary syndromes. Eur Heart J 2004;25:190-198.
19. TASC Working Group. Management of peripheral arterial disease; transatlantic inter-society consensus. J Vasc Surg 2000;31:S104.
20. Jahnke T, Voshage G, Muller-Hulsbeck S, Grimm J, Heller M, Brossmann J. Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease. J Vasc Interv Radiol 2002;13:257-266.
21. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002;106:1505-1509.
22. Scheinert D, Scheinert S, Sax J, Piorkowski C, Braunlich S, Ulrich M, Biamino G, Schmidt A. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. Am Coll Cardiol 2005;45:312-315.
23. Hiatt WR. Pharmacologic therapy for peripheral arterial disease and claudication. J Vasc Surg 2002;36:1283-1291.
24. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 1991;83(Suppl 2):I70-I80.
25. Golledge J, Ferguson K, Ellis M, Sabharwal T, Davies AH, Greenhalgh RM, Powell JT, et al. Outcome of femoropopliteal angioplasty. Ann Surg 1999;229:146-153.
26. Jamsen TS, Manninen HI, Jaakkola PA, Matsi PJ. Long-term outcome of patients with claudication after balloon angioplasty of the femoropopliteal arteries. Radiology 2002;225:345-352.
27. Tielbeek AV, Vroegindeweij D, Buth J, Landman GH. Comparison of balloon angioplasty and Simpson atherectomy for lesions in the femoropopliteal artery: angiographic and clinical results of a prospective randomized trial. J Vasc Interv Radiol 1996;7:837-844.
28. Zeller T, Rastan A, Schwarzwalder U, Frank U, Burgelin K, Amantea P, Muller C, Flugel PC, Neumann FJ. Percutaneous peripheral atherectomy of femoropopliteal stenoses using a new-generation device: six-month results from a single-center experience. J Endovasc Ther 2004;11:676-685.
29. Fava M, Loyola S, Polydorou A, Papapavlou P, Polydorou A, Mendiz O, Joye JD. Cryoplasty for femoropopliteal arterial disease: late angiographic results of initial human experience. J Vasc Interv Radiol 2004;15:1239-1243.
30. Laird J, Jaff MR, Biamino G, McNamara T, Scheinert D, Zetterlund P, Moen E, Joye JD. Cryoplasty for the treatment of femoropopliteal arterial disease: results of a prospective, multicenter registry. J Vasc Interv Radiol 2005;16:1067-1073.
31. AbuRahma AF, Robinson PA, Holt SM. Prospective controlled study of polytetrafluoroethylene versus saphenous vein in claudicant patients with bilateral above knee femoropopliteal bypasses. Surgery 1999;126:594-601.
32. Ballotta E, Renon L, Toffano M, Da Giau G. Prospective randomized study on bilateral above-knee femoropopliteal revascularization: polytetrafluoroethylene graft versus reversed saphenous vein. J Vasc Surg 2003;38:1051-1055.
33. Bergamini TM, Towne JB, Bandyk DF, Seabrook GR, Schmitt DD. Experience with in situ saphenous vein bypasses during 1981-1989: determinant factors of long-term patency. J Vasc Surg 1991;13:137-147.
34. Bergan JJ, Veith FJ, Bernhard VM, Yao JS, Flinn WR, Gupta SK, Scher LA, Samson RH, Towne JB. Randomization of autogenous vein and polytetrafluorethylene grafts in femoral-distal reconstruction. Surgery 1982;92:921-930.
35. Burger DH, Kappetein AP, Van Bockel JH, Breslau PJ. A prospective randomized trial comparing vein with polytetrafluoroethylene in above-knee femoropopliteal bypass grafting. J Vasc Surg 2000;32:278-283.
36. Faries PL, Logerfo FW, Arora S, Hook S, Pulling MC, Akbari CM, Campbell DR, Pomposelli FB, Jr. A comparative study of alternative conduits for lower extremity revascularization: all-autogenous conduit versus prosthetic grafts. J Vasc Surg 2000;32:1080-1090.